Update on the treatment of non-small-cell lung cancer: focus on the cost-effectiveness of new agents.

about

Update on the treatment of non-small-cell lung cancer: focus on the cost-effectiveness of new agents.

Item

http://www.wikidata.org/entity/Q36765647

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Update on the treatment of non ...... t-effectiveness of new agents.

@ast

Update on the treatment of non ...... t-effectiveness of new agents.

@en

type

Item

label

Update on the treatment of non ...... t-effectiveness of new agents.

@ast

Update on the treatment of non ...... t-effectiveness of new agents.

@en

prefLabel

Update on the treatment of non ...... t-effectiveness of new agents.

@ast

Update on the treatment of non ...... t-effectiveness of new agents.

@en

P1476

Update on the treatment of non ...... t-effectiveness of new agents.

@en

P2093

A Vergnenègre

http://www.w3.org/2001/XMLSchema#string

P2860

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3.

Economics of treatments for non-small cell lung cancer.

Cost effectiveness of treatment with new agents in advanced non-small-cell lung cancer: a systematic review.

Projections of the cost of cancer care in the United States: 2010-2020.

Lung cancer treatment costs, including patient responsibility, by disease stage and treatment modality, 1992 to 2003

Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer

Evaluation of trends in the cost of initial cancer treatment

Economic evaluation of bevacizumab in the treatment of non-small cell lung cancer (NSCLC).

P304

137-141

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/CEOR.S30670

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Christos Chouaid

Isabelle Borget

P577

2013-04-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23630426

http://www.w3.org/2001/XMLSchema#string

P932

3626258

http://www.w3.org/2001/XMLSchema#string